• ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US
No announcement available or all announcement expired.
NSCI (LON) 5,50 GBX
  • ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • CORPORATE GOVERNANCE
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US

Significant Reduction in Re-Admissions of High-Risk CHF Patients Achieved by Wanda and Partner HRS

May 21, 2018
-
News, RNS Announcements

London, UK – May 21st, 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation Group, announces that Wanda and Health Resource Solutions (HRS), Wanda’s partner, have successfully achieved a reduction of 46% in the number of hospitals re-admissions in their high-risk Congestive Heart Failure patient population. Wanda’s real-time technology continuously assesses patient status and allows for detection of adverse events up to 7 days in advance of their occurrence, which has a significant and positive impact on patients’ lives and provides a strong rationale for rolling out the system to more patients beyond the 576 HRS patients enrolled to date.

 

Commenting on the news, Francois R. Martelet, NetScientific’s Chief Executive Officer and Chairman of Wanda, said: “The data are impressive as patients with congestive heart failure typically have a very high re-admission rate. This demonstrates the invaluable potential Wanda’s technology has in streamlining care and improving patient outcomes. We are entering a new digital era of healthcare in which we firmly believe Wanda can play a pivotal role, and we are very pleased to see the collaboration with HRS working so well.”

 

NetScientific holds a 62% stake on a fully diluted basis in Wanda.

 

For more information, please contact:

 

  NetScientific

François R. Martelet, M.D., CEO

Ian Postlethwaite, CFO

Tel: +44 (0)20 3514 1800
 

  Consilium Strategic Communications

Mary-Jane Elliott Jessica Hodgson /

Chris Welsh / Laura Thornton

 

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

Stifel Nicolaus Europe Limited (NOMAD and Broker)

Jonathan Senior / David Arch / Ben Maddison

 Tel: +44 (0) 20 7710 7600

 

 

About NetScientific

 

NetScientific is a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercialising technologies that significantly improve the health and well-being of people with chronic diseases. For more information, please visit the website at www.netscientific.net

 

 

Machine Learning, Care Transitions, and Clinical Pathways Reduce CHF Readmissions by 46%

Chicago, IL – May 21st, 2018 – Health Resource Solutions (HRS Home Health) announces the company achieved another milestone in their progressive approach to improve care for chronically ill patients. Over the last two quarters, (Q4 2017 and Q1 2018), HRS attained a 46% reduction in the readmission rate of their Congestive Heart Failure patient population. This achievement stems from the marriage of a dynamic patient management solution driving care transitions and the clinical pathway protocols at HRS Home Health.

 

The CHF patient population, notably one of the most highly readmitted diagnostic groups nationwide, has been engaged in this approach during the last six months. The CHF program utilizes the dynamic patient management system, provided by Wanda, Inc., which is embedded with machine learning to power the clinical decision process. Wanda continuously evaluates subtle changes in a patient’s clinical, social, and behavioral health determinants to warn when an adverse event is likely to transpire – seven days in advance of the occurrence. Prior to engaging this methodology, this group of patients had a 34% 30-day readmission rate making them among the highest readmission rate groups for HRS.  By integrating this technology with services and care pathways, HRS reduced the 30 day readmission rate to 18.6%

 

“HRS is excited to drive value and make a measurably positive impact on the lives of our CHF population.  With Wanda, our clinicians are able to make more informed and timely decisions, which help us avoid unnecessary adverse events for our patients,” said Glenn Steigbigel, CEO of HRS. “As providers, we are imbuing clinical processes with modern technology, which empowers our clinical teams with real-time actionable information to improve patient care. This approach benefits patients by providing them with the support they need while simultaneously reducing the total cost of care.”

 

As high-risk CHF patients are identified, Wanda facilitates real-time case management.  This is accomplished by empowering clinicians with virtual intervention features to proactively engage them in care plan adherence and prevent avoidable adverse events.

 

“The incredible results that HRS is achieving are fantastic and we look forward to continuing our partnership to improve care,” said Foad Dabiri, CEO Wanda, Inc. “Proactive, real-time data science is how healthcare will achieve the levels of care and compliance needed to meet today’s expectations.”

 

About Health Resource Solutions

HRS is the largest privately owned high-tech nursing and rehabilitation home health agency in Chicago, IL. Since 2006, HRS has integrated data and technologies with home health services to measure outcomes and increase value for patients leading to improved outcomes and efficiencies. More information about HRS can be found at http://www.healthhrs.net

 

About Wanda, Inc

Wanda is dedicated to advancing the effectiveness and efficiency of medicine by using machine learning and modern software applications that empower payers and providers to better manage the risk and care of patients dramatically lowering the cost of care and improving outcomes. More information about Wanda can be found at http://www.yourwanda.com

 

FacebookTweetLinkedin
← PREVIOUS POST
Notice of AGM and Annual Report & Accounts
NEXT POST →
ProAxsis to Present New Data Underscoring the Importance of Neutrophil Elastase in COPD at ATS 2018
News
  • Glycotest receives 2nd $3m tranche of $10m finance
  • Appointment to the Board
  • PDS collaborates with Merck in Phase 2 studies
  • PDS prioritise PDS0101 in High risk HPV to Phase 2
  • PDS – positive data for immunotherapy treatment
INVESTORS
  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • Corporate Governance
  • News
Categories
  • Glycotest
  • Media
  • News
  • PDS Biotechnology
  • ProAxsis
  • RNS Announcements
Archives
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • March 2014
  • February 2014
  • September 2013

NetScientific plc

PO Box 76075
London
EC3P 3DX

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • Corporate Governance
  • News
copyright
Terms of Use
Significant Reduction in Re-Admissions of High-Risk CHF Patients Achieved by Wanda and Partner HRS - NetScientific